Table 4.

Additional analysis for colorectal cancer mortality in NHANES III participants

HRs (95% CI) comparing those with CRP levels >0.3 mg/dL to levels ≤0.3 mg/dL
Model 3a3.29 (1.87–5.79)
Additional analysisb
 Using waist-to-hip ratio instead of BMI in the model3.10 (1.77–5.41)
 Excluding those with regular NSAID use3.99 (2.01–7.90)
 Excluding women with any hormone use3.02 (1.65–5.52)
 Excluding those with h/o heart attack, CHF, stroke, or cancer3.79 (1.86–7.71)
 Excluding those who died of colorectal cancer within 3 years of survey3.34 (1.77–6.28)
 Duration of follow-up: 5 years2.55 (0.64–10.14)
 Duration of follow-up: 10 years3.72 (1.44–9.59)
Adjusting for additional covariates
 Model 3 + fiber intake, g/day2.99 (1.63–5.46)
 Model 3 + total saturated fatty acid intake, g/day2.98 (1.63–5.42)
 Model 3 + total calcium intake, mg/day2.98 (1.64–5.44)
 Model 3 + total vitamin D intake, mcg/day2.99 (1.64–5.43)
 Model 3 + serum C-peptide concentration, pmol/mL3.36 (1.89–5.97)
 Model 3 + serum folate levels, ng/mL3.29 (1.84–5.89)
 Model 3 + white blood cell count3.37 (1.83–6.21)
 Model 3 + neutrophil–lymphocyte ratio3.05 (1.60–5.81)
 Model 3 + plasma fibrinogen, mg/dL3.43 (1.56–7.51)
 Model 3 + serum albumin, g/dL2.97 (1.69–5.20)

Abbreviations; CHF, congestive heart failure; h/o, history of.

  • aAdjusted for age, gender, race–ethnicity, level of education, annual family income, BMI, pack-years of smoking, serum cotinine levels, alcohol consumption, physical activity, hypertension status, diabetes status, hypercholesterolemia, supplement use, NSAID use, and hormone use in women.

  • bHRs adjusted for variables in model 3.